Summary: Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Failures

Recommended and alternative regimens listed by evidence level and alphabetically for:

Sofosbuvir-Based Treatment Failures, With or Without Compensated Cirrhosisa 

RECOMMENDED DURATION RATING

Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)b

12 weeks I, A
ALTERNATIVE DURATION RATING

Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) except for NS3/4 protease inhibitor inclusive combination DAA regimen failuresc

  • Not recommended for genotype 3 infection with sofosbuvir/NS5A inhibitor experience.
16 weeks I, A
a For decompensated cirrhosis, please refer to the appropriate section.
b Genotype 3: Add weight-based ribavirin if cirrhosis is present and there are no contraindications.
​c This regimen is not recommended for patients with prior exposure to an NS5A inhibitor plus NS3/4 PI regimens (eg. Elbasvir/grazoprevir).

 

Last update: 
January 21, 2021
Top